Shameze Rampertab 4
4 · ASENSUS SURGICAL, INC. · Filed Aug 22, 2024
Insider Transaction Report
Form 4
Shameze Rampertab
EVP, Chief Financial Officer
Transactions
- Disposition to Issuer
Common Stock
2024-08-22−595,372→ 0 total - Disposition to Issuer
Restricted Stock Units
2024-08-22−116,666→ 0 totalExercise: $0.00→ Common Stock (116,666 underlying) - Disposition to Issuer
Restricted Stock Units
2024-08-22−330,300→ 0 totalExercise: $0.00→ Common Stock (330,300 underlying) - Disposition to Issuer
Stock Options
2024-08-22−396,800→ 0 totalExercise: $0.26→ Common Stock (396,800 underlying) - Disposition to Issuer
Restricted Stock Units
2024-08-22−62,417→ 0 totalExercise: $0.00→ Common Stock (62,417 underlying) - Disposition to Issuer
Restricted Stock Units
2024-08-22−660,600→ 0 totalExercise: $0.00→ Common Stock (660,600 underlying)
Footnotes (6)
- [F1]The reported securities were disposed of pursuant to the terms of an Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 6, 2024, by and among Asensus Surgical, Inc., a Delaware corporation ("Asensus"), KARL STORZ Endoscopy-America, Inc., a California corporation ("Parent"), and Karl Storz California Inc., a California corporation ("Merger Sub"), pursuant to which Merger Sub merged with and into Asensus with Asensus as the surviving corporation of the merger (the "Merger"). Upon the effective time of the Merger, the reporting person received $0.35 in cash, without interest and less applicable withholding taxes for each share of common stock.
- [F2]The reported securities include 179,084 shares of common stock issued upon the acceleration and vesting of performance-based restricted stock units.
- [F3]Upon the closing of the Merger, these equity awards are cancelled and converted into the contingent right to receive a cash payment of $0.09 per underlying share of common stock only upon satisfaction of all vesting conditions.
- [F4]Each restricted stock unit ("RSU") represents the right to receive one share of the Registrant's common stock.
- [F5]Each performance-based restricted stock unit ("PRSU") represents the right to receive one share of the Registrant's common stock.
- [F6]Upon the closing of the Merger, these equity awards are cancelled and converted into the contingent right to receive a cash payment of $0.35 per underlying share of common stock only upon satisfaction of all vesting conditions.